Can the prognostic nutritional index predict survival in patients with gastric and esophagogastric junction adenocarcinoma?
- 1Department of Surgical Oncology, Ankara Etlik City Hospital
- 2Department of Surgical Oncology, University of Health Sciences Ankara Oncology Training and Research Hospital
- 3Department of Anesthesiology and Reanimation, University of Health Sciences Ankara Oncology Training and Research Hospital
Abstract
Background: This study aimed to evaluate the prognostic significance of the preoperative Prognostic Nutritional Index (PNI) for overall survival (OS) and disease-free survival (DFS) in patients with gastric and gastroesophageal junction adenocarcinoma.
Methods: We retrospectively analyzed the data from 300 patients undergoing curative gastrectomy at Ankara Oncology Training and Research Hospital between January 2013 and 2021. We calculated PNI using the formula: PNI = (10 × serum albumin [g/dL]) + (0.005 × total lymphocyte count). Using receiver operating characteristic (ROC) curve analysis, we determined the optimal PNI cut-off value as 45.83 and subsequently stratified patients into two groups: those with PNI ≥ 45.83 and those with PNI < 45.83. We then evaluated overall survival (OS) and disease-free survival (DFS) using the Kaplan–Meier method.
Results: Our findings showed that patients with PNI < 45.83 had significantly shorter OS and DFS compared to those with PNI ≥ 45.83 (OS: 42 months vs. 90 months; DFS: 39 months vs. 84 months; p < 0.001). The multivariate analysis demonstrated low PNI, advanced T-stage, a higher number of metastatic lymph nodes, and Bormann type 3 tumors to be independent negative prognostic factors for both OS and DFS.
Conclusions: Low preoperative PNI was associated with poorer OS and DFS in patients with gastric and gastroesophageal junction adenocarcinoma. PNI may contribute to preoperative risk assessment; however, prospective validation is required before its routine clinical use.
Related
- Prognostic impact of neoadjuvant therapy and nomogram development in early-stage and locally advanced Siewert type II adenocarcinoma of the esophagogastric junction based on the SEER database
- Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy
- Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT database
- Prognostic Modeling of Lysosomal Cell Death Signatures in Lung Adenocarcinoma: A Machine Learning Framework for Survival Outcome Prediction
- Neoadjuvant toripalimab plus concurrent chemoradiotherapy for locally advanced adenocarcinoma of the esophagogastric junction: a phase II trial
BibTeX
@article{sagdıc2026prognostic,
title = {{Can the prognostic nutritional index predict survival in patients with gastric and esophagogastric junction adenocarcinoma?}},
author = {Mehmet Furkan Sağdıç and Burak Dinçer and Güldeniz Argun and Ahmet Karayiğit and Cihangir Özaslan},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1872975},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1872975/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Can the prognostic nutritional index predict survival in patients with gastric and esophagogastric junction adenocarcinoma?
AU - Mehmet Furkan Sağdıç
AU - Burak Dinçer
AU - Güldeniz Argun
AU - Ahmet Karayiğit
AU - Cihangir Özaslan
PY - 2026
DA - 2026/10/22
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1872975
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1872975/full
AB - Background: This study aimed to evaluate the prognostic significance of the preoperative Prognostic Nutritional Index (PNI) for overall survival (OS) and disease-free survival (DFS) in patients with gastric and gastroesophageal junction adenocarcinoma. Methods: We retrospectively analyzed the data from 300 patients undergoing curative gastrectomy at Ankara Oncology Training and Research Hospital between January 2013 and 2021. We calculated PNI using the formula: PNI = (10 × serum albumin [g/dL]) + (0.005 × total lymphocyte count). Using receiver operating characteristic (ROC) curve analysis, we determined the optimal PNI cut-off value as 45.83 and subsequently stratified patients into two groups: those with PNI ≥ 45.83 and those with PNI < 45.83. We then evaluated overall survival (OS) and disease-free survival (DFS) using the Kaplan–Meier method. Results: Our findings showed that patients with PNI < 45.83 had significantly shorter OS and DFS compared to those with PNI ≥ 45.83 (OS: 42 months vs. 90 months; DFS: 39 months vs. 84 months; p < 0.001). The multivariate analysis demonstrated low PNI, advanced T-stage, a higher number of metastatic lymph nodes, and Bormann type 3 tumors to be independent negative prognostic factors for both OS and DFS. Conclusions: Low preoperative PNI was associated with poorer OS and DFS in patients with gastric and gastroesophageal junction adenocarcinoma. PNI may contribute to preoperative risk assessment; however, prospective validation is required before its routine clinical use.
SN - 2234-943X
ER -